Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 215 results for chronic kidney disease

  1. Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)

    This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  2. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)

    NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .

  3. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

  4. The impact of advanced kidney disease on the natriuretic peptide threshold for diagnosing heart failure:- What are the optimal NT-proBNP thresholds for diagnosing heart failure in people with stage IIIb, IV or V chronic kidney disease?

    Recommendation ID NG106/4 Question The impact of advanced kidney disease on the natriuretic peptide threshold for...

  5. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  6. Hyperphosphatemia in people with CKD stage 4 or 5: What are people with CKD and their family members and carers views and beliefs about taking oral phosphate binders?

    NG203/5 Question Hyperphosphatemia in people with CKD stage 4 or 5: What are people with CKD and their family members and...

  7. Self-management of CKD: Does the provision of educational and supportive interventions to people with CKD by healthcare professionals increase the person's skills and confidence in managing their conditions and improve clinical outcomes?

    Question Self-management of CKD: Does the provision of educational and supportive interventions to people with CKD by...

  8. Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (HTG544)

    Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the ARCHITECT and ALINITY i Urine NGAL assays, BioPorto NGAL test and NephroCheck test.

  9. Managing anaemia: For adults, children and young people with CKD and anaemia, what is the diagnostic accuracy of eGFR thresholds of 60, 45, and 30 ml/min/1.73 m2 for determining whether the anaemia is due to CKD?

    Question Managing anaemia: For adults, children and young people with CKD and anaemia, what is the diagnostic accuracy of eGFR...

  10. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

  11. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

  12. Management of anaemia of CKD with concurrent illness: What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of CKD in people who are receiving erythropoietic stimulating agents (ESAs) and have a significant concurrent acute infectious illness?

    of anaemia of CKD with concurrent illness: What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of...

  13. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (HTG391)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

  14. Frequency of review: What is the most clinical and cost-effective frequency of review for children and young people with CKD?

    people with CKD? Any explanatory notes(if applicable) Source guidance details Comes from guidance Chronic kidney disease:...